Abstract Cardiovascular diseases are approximately three times higher in patients with neurological deficits than in patients without neurological deficits. MicroRNA-126 (MiR-126) facilitates vascular remodeling and decreases fibrosis and is emerging as an important factor in the pathogenesis of cardiovascular diseases and cerebral stroke. In this study, we tested the hypothesis that decreased miR-126 after ischemic stroke may play an important role in regulating cardiac function. Wild-type (WT), specific conditional-knockout endothelial cell miR-126 (miR-126 EC−/− ), and miR-126 knockout control (miR-126 fl/fl ) mice were subjected to distal middle cerebral artery occlusion (dMCAo) (n = 10/group). Cardiac hemodynamics and function were measured using transthoracic Doppler echocardiography. Mice were sacrificed at 28 days after dMCAo. WT mice subjected to stroke exhibited significantly decreased cardiac ejection fraction and increased myocyte hypertrophy, fibrosis as well as increased heart inflammation, infiltrating macrophages, and oxidative stress compared to non-stroke animals. Stroke significantly decreased serum and heart miR-126 expression and increased miR-126 target genes, vascular cell adhesion protein-1, and monocyte chemotactic protein-1 gene, and protein expression in the heart compared to non-stroke mice. EC−/− mice exhibited significantly decreased cardiac function and increased cardiomyocyte hypertrophy, fibrosis, and inflammatory factor expression after stroke compared to miR-126 
Introduction
Stroke is a prominent cause of mortality and long-term disability and is accompanied by unusually high social and medical costs [1, 2] . The major causes of death in stroke-related mortalities are a consequence of neurological damage and/or cardiovascular complications [3] . Co-morbidity of stroke with hypertension, diabetes, or cardiac abnormalities aggravates stroke outcome, disability, risk of recurrent stroke, and mortality [4, 5] . However, cardiac dysfunction is encountered frequently among stroke patients, even in the absence of primary heart disease [6, 7] . Post-stroke neurological deficits increase the risk of cardiovascular diseases roughly by three times [3] , and the ischemic brain transmits indirect cell death signals to the heart [8] . Necropsy analyses of patients who suffered a fatal cerebral stroke indicate a high prevalence of coronary atherosclerosis and myocardial infarction [9] . Patients can develop myocardial injuries after stroke even when patients do not have pre-existing cardiac diseases [6, 7, [10] [11] [12] . However, it is unclear how cerebral ischemic stroke regulates cardiac function, what are the direct effects of stroke on cardiac function, and what are the underlying molecular mechanisms. In this study, using a cerebral ischemic stroke model in mice, we study the Bbrain and heart interaction^after stroke.
MicroRNAs (miRs) are small non-coding RNA molecules that regulate several gene expressions, pathways, and complex biological networks at the cellular level acting either exclusively or together with other miRs [13] . MiRs regulate both transcriptional and post-transcriptional gene expression as well as regulate several circuits involved in tissue repair, inflammation, hypoxia-response, and angiogenesis [14] . MicroRNA-126 (MiR-126) is endothelial cell (EC) specific and plays a key role in regulating EC function, controlling angiogenesis, and maintaining vascular integrity [14] . MiR-126 facilitates vascular remodeling, decreases fibrosis in multiple organs, and has been reported to be beneficial in the treatment of atherosclerosis and re-stenosis [14, 15] . MiR-126 is emerging as a key player in the pathogenesis of cardiovascular diseases and ischemic stroke [16, 17] and is involved in endovascular inflammation and platelet activation [18] . MiR-126 expression in serum is positively correlated with left ventricular ejection fraction (LVEF) [18] . To date, the direct effects and role of miR-126 on the interaction between brain and heart after stroke have not been investigated. In this study, we hypothesize that the decrease of miR-126 expression after stroke may play an important role in regulating cardiac function, and we show that cerebral ischemic stroke in mice decreases heart miR-126 expression and increases cardiac dysfunction.
Materials and Methods
Extraluminal Permanent Distal Middle Cerebral Artery Occlusion (dMCAo) Model Adult (3-4 months) male wildtype (WT) C57/BJ6L mice were purchased from Jackson Laboratory. Mice were anesthetized with 3.5% isoflurane in a mixture of N 2 O:O 2 (2:1) and maintained at 0.5% ∼ 1.5% isoflurane using a facemask and were subjected to sham control or right extraluminal permanent dMCAo, as previously described [19, 20] . Briefly, a midline incision was opened between the orbit and the ear. A small burr hole was produced in the skull. The main branch of the MCA was coagulated with a small heater probe, and the vessel was transected. The same procedures without artery coagulation were performed on sham control mice (n = 10/group).
Generation of Specific Conditional EC MiR-126 Knockout (MiR-126 EC−/− ) Mice Briefly, we crossbred PDGFiCreER:miR-126flox/flox with miR-126flox/flox mice [21, 22] (these transgenic mice were generously provided by Dr. Calvin Kuo, Stanford University). Genotyping was perf o r m e d a t 4 w e e k s a f t e r b i r t h . T h e n , b o t h t h e PDGFiCreER:miR-126flox/flox and miR-126flox/flox mice were treated with tamoxifen (1 mg/10 g body weight of tamoxifen dissolved in corn oil); 4 doses were administered e v e r y o t h e r d a y i . p . T h e t a m o x i f e n -t r e a t e d PDGFiCreER:miR-126flox/flox mice have specific EC miR-126 deletion (called miR-126
). fl/fl mice were employed as knockdown control. MiR-126 EC−/− and miR-126 fl/fl mice were subjected to dMCAo (n = 10/group). , as previously reported [23] . Mice were trained for 3 days before echocardiography. Briefly, the mouse was picked up by the nape of the neck and held firmly in the palm of one hand in the supine position. In our experience, most mice develop bradycardia during the first training session; however, with repeated training the bradycardia disappears and mice remain calm. After training, the left hemithorax was shaved and a pre-warmed ultrasound transmission gel was applied to the chest. LVEF was measured using the formula: LVEF = [(LVAd − LVAs) / LVAs × 100], where LVAd is LV diastolic area and LVAs is LV systolic area. All primary measurements were digitized by goal-directed, diagnostically driven software and 3 beats were averaged for each measurement.
Cardiac Function Measurements
Histological and Immunohistochemical Assessment Mice were sacrificed at 28 days after dMCAo. The brain and the heart were isolated and were fixed by 4% paraformaldehyde before being embedded in paraffin. Brain coronal tissue sections (bregma -1 mm to +1 mm) were cut (6 μm thick) and stained with hematoxylin and eosin for calculation of lesion volume [24] . Heart coronal sections (6 μm thick) were cut, and PicroSirius Red (PSR) staining was employed to assess myocyte cross-sectional area (MCSA, identifies cardiomyocyte size) [25] and interstitial collagen fraction (ICF) measurement [26] . ICF is a measurement of cardiac interstitial and perivascular fibrosis, measured by a percent rate of PSRstained collagen area to total myocardial area. For immunostaining, antibodies against mouse CD68 (ED1, a marker for monocytes/macrophages; 1:30, Bio-Rad); transforming growth factor (TGF-β; 1:500, Santa Cruz); monocyte chemotactic protein-1 (MCP-1; 1:100, Abcam); vascular cell adhesion molecule 1 (VCAM-1, 1:200, Santa Cruz); NADPH oxidase-2 (NOX2; 1:400, BD Bioscience) were employed. Negative controls were processed in a similar fashion but without the primary antibody.
Immunostaining Quantification Five slides from each heart, with each slide containing 3 fields of view, were digitized under a ×20 objective (Olympus BX40) using a 3-CCD color video camera (Sony DXC-970MD) interfaced with an MCID image analysis system (Imaging Research). Image analysis was performed in a blinded fashion. Positive areas of PSR, TGF-β, NOX2, MCP-1 and positive cell number of ED1 in the fields of view were calculated.
Mouse Neonatal Cardiomyocyte Culture Mouse neonatal hearts were enzymatically dissociated into a single cell suspension, as previously described [27] . Briefly, the hearts were finely cut and broken up into single cells in 0.1% collagenase/ dispace (Roche EC − / − E C -Exo) mice were used to treat ischemic cardiomyocytes in culture. Briefly, brain ECs were isolated from adult male miR-126 fl/fl and miR-126 EC−/− mice following a previously described protocol [28] . Primary brain ECs were cultured up to 3 passages and then cultured in exosomedepleted FBS media (Systembio) for 3 days. After exosomes were isolated, exosome-depleted FBS was used for all further cell cultures. EC-Exo was isolatedusing ExoQuick-TC, following standard protocol and suspended in PBS. EC-Exo concentration was quantified using the IZON qNano device (Izon, Christchurch, New Zealand). To decrease the heterogeneity of EC-Exo treatment, we tightly controlled the EC culture conditions, such as EC passage, density, and culture time. Protein concentration was determined for each EC-Exo doseemployed.
To induce cardiomyocyte ischemia in vitro, oxygenglucose deprivation (OGD) was performed. Cardiomyocyte culture media was replaced with glucose and serum-free media and placed in a hypoxia chamber (Forma Anaerobic System, Thermo Fisher Scientific) for 2 h of OGD at 37°C. The experimental groups include (1) cardiomyocyte control; (2) cardiomyocytes +20 ng/ml miR-126 fl/fl -EC-Exo; (3) cardiomyocytes +20 ng/ml miR-126 EC−/− EC-Exo for 24 h. K n o c k d o w n o f M i R -1 2 6 i n C u l t u r e d M o u s e Cardiomyocyte To knockdown miR-126 expression in cultured cardiomyocytes, mmu-miR-126-3p inhibitor (miR-126 knockdown),or scrambled negative control inhibitor (Thermo Scientific) was performed using an electroporation transfection method. Briefly, mouse cardiomyocytes were harvested and resuspended in 95 μl Ingenio electroporation solution (Mirus) and in 5 μl of 20 μM miR-126 inhibitor or scrambled control (Dharmacon). The cell suspension was placed in an Ingenio cuvette (Mirus) and electroporated in a Lonza Nucleofector using program Y-01. Then cells were cultured for 2 days and miR-126 expression was measured.
Cardiomyocyte Structure Changes F-actin staining was performed to identify cell size. Briefly, fixed cells were labeled with anti-F-actin (CytoPainter F-actin Staining KitGreen Fluorescence, Abcam) and nuclei were labeled with DAPI. For cell surface area measurements, 6 areas were randomly selected from each 10-mm cover-slipped area [29] .
Western Blot Assay Protein was isolated from samples using Trizol (Invitrogen). Protein concentration was measured using the BCA kit (Thermo Fisher Scientific). MCP-1 (1:1000, Abcam), NOX2 (1:1000, BD Bioscience), TGF-β (1:1000, Santa Cruz), or VCAM-1 (1:500, Santa Cruz) primary antibodies were employed. Anti-β-actin (1:10,000; Abcam) antibody was loaded for control measurements.
Real-Time PCR We isolated the total RNA with TRIzol (Invitrogen) to make cDNA using the M-MLV (Invitrogen) standard protocol. The TaqMan real-time PCR was used and run on a ViiA7 system (Applied Biosystems). Each sample was tested in triplicate, and analysis of relative gene expression data was performed using the 2 -ΔΔCT method. The following primers for real-time PCR were designed using Primer Express software (Applied Biosystems): MiR-126 Measurement MiR-126 expression was measured by TaqMan miRNA assay (Life Technology), as previously described [30] . Briefly, samples (serum, heart, or cultured cells) were lysed in Qiazol reagents and the total RNA was isolated. PCR amplification was performed with the TaqMan miRNA assay kit according to the manufacturer's protocols, with U6 snRNA as an internal control.
Statistical Analysis All data are expressed as mean ± SE. Independent two-sample t-test was used to compare the differences between dMCAo and non-stroke groups. W h e n m u l t i p l e c o m p a r i s o n s w e r e p e r f o r m e d , Hochberg's step-up procedure was used to adjust pvalues. The pair-wise comparison was set at 0.05.
Results
Cerebral Ischemic Stroke Induces Cardiac Dysfunction, Cardiomyocyte Hypertrophy, Fibrosis, Inflammation, and Oxidative Stress Compared to Non-stroke Mice
To test whether stroke induces cardiac dysfunction, echocardiography was employed in conscious mice at 28 days after stroke. The ischemic lesion volume in WT-dMCAo mice was 10.79% ± 0.97%. Figure 1a shows that stroke significantly decreased cardiac function identified by decreased LVEF compared to non-stroke mice (p < 0.05). Cardiac fibrosis was evident both in the perivascular and in the myocardial interstitial area in the dMCAo group. Figure 1b shows that stroke significantly increased myocyte cross-sectional area and interstitial fibrosis compared to non-stroke mice. These data indicate that stroke initiates myocyte hypertrophy and interstitial fibrosis.
To test the mechanisms of stroke-induced cardiac dysfunction, oxidative stress, inflammatory factor (infiltrating macrophages, ED1), TGF-β and oxidative stress (NOX2) expression were measured in the heart. Figure 2 shows that stroke significantly increased ED1, TGF-β, and NOX2 expression in the heart compared to WT control mice, as measured by immunostaining and Western blot.
Cerebral Ischemic Stroke Significantly Decreases Heart and Serum MiR-126 and Increases MiR-126 Targets MCP-1 and VCAM-1 Expression in Heart Tissue
To test possible mechanisms of stroke-induced cardiac dysfunction, miR-126 expression was measured in blood serum and heart tissue. Figure 3a shows that dMCAo significantly decreased serum and heart miR-126 expression compared to non-stroke mice.
To test whether stroke regulates miR-126 target gene and protein expression, selected specific miR-126 target genes and proteins (MCP-1 and VCAM-1 [31, 32] ) were measured. Figure 3b , c shows that stroke increased heart tissue MCP-1 and VCAM-1 gene and protein expression compared to nonstroke control. The data indicate that stroke decreased miR-126 and increased its targets, MCP-1 and VCAM-1 gene and protein expression in the heart tissue. Figure 5a , b shows that stroke in miR-126 EC−/− mice significantly increased heart TGF-β and NOX2 expression compared to stroke in miR-126 fl/fl mice. MiR-126 EC−/− stroke mice also exhibit significantly increased VCAM-1 and MCP-1 gene expression in the heart tissue compared to miR-126 fl/fl stroke mice (Fig. 5d ). To test whether stroke regulates miR-126 expression in miR-126 EC−/− mice, miR-126 expression in serum and heart were measured. Figure 5c shows that miR-126 EC−/− mice had lower levels of miR-126 expression in serum and heart than miR-126 fl/fl mice (p < 0.05). Stroke exacerbates the decrease of miR-126 expression in heart in both miR-126 EC−/− and miR-126 fl/fl mice. 
MiR-126 Regulates Cardiomyocyte Hypertrophy In vitro
To confirm whether miR-126 directly regulates cardiomyocyte hypertrophy, cell size was measured by surface area calculation using fluorescence microscopy after anti-F-actinin staining in cultured cardiomyocytes. Using sarcomeric aactinin staining, we found that 95% of cultured cells are cardiomyocytes (Fig. 6a) . In addition, knockdown of miR-126 in cardiomyocytes significantly decreased cardiomyocyte miR-126 expression (Fig. 6b ) and increased MCP-1 and VCAM-1 expression (Fig. 6c) compared to scrambled control. MiR-126 knockdown in cardiomyocyte also significantly increased cardiomyocyte size compared to scrambled knockdown control (Fig. 6d) . However, knockdown of miR-126 in cardiomyocytes did not affect cardiomyocyte cell death compared to scrambled cardiomyocyte knockdown control (data not shown). The data indicate that miR-126 regulates cardiomyocyte hypertrophy.
MiR-126 is a secreted miR and is primarily expressed in endothelial cells [33] . We first measured miR-126 expression in exosomes derived from brain endothelial cells of miR- 
Discussion
In this study, we found that stroke induces cardiac dysfunction and increases inflammatory and oxidative stress in the heart compared to non-stroke mice. Stroke decreases serum and heart miR-126 and increases miR-126 target gene and protein expression. Using specific conditional miR-126 EC−/− mice, we are the first to demonstrate that miR-126 EC−/− stroke mice have more severe cardiac dysfunction and hypertrophy compared to miR-126 fl/fl stroke mice, suggesting the importance of miR-126 as a mediator of brain and heart interaction after stroke.
Brain and Heart Interaction after Stroke Acute cerebrovascular disease, acute brain injury, intracranial inflammation and intracranial hypertension can all cause cardiac injury [3] . During the first 3 months following acute ischemic stroke, 19.0% of patients encounter at least one major adverse cardiac episode [3] ; approximately 28.5% of stroke patients have an LVEF less than 50% [3] ; 13-29% of stroke patients have systolic dysfunction [34] ; and 35-74% have ischemic changes on electrocardiography [3] . Therefore, there may be a causal relationship between brain damage and heart dysfunction. In this study, we demonstrated that stroke leads to heart dysfunction at 28 days after stroke, demonstrated by decreased LVEF, as well as increased cardiac interstitial fibrosis and hypertrophy compared to non-stroke mice. Thus, there is a compelling need to investigate mechanisms of stroke-induced heart dysfunction, which may help to develop therapeutic approaches specifically designed to reduce neurological deficits and also to prevent or reduce cardiac dysfunction after stroke.
MiR-126 May Contribute to Brain-Heart Interaction after Stroke Select miRs are altered by stroke and cardiovascular dysfunction [35] . Circulating miRs mediate intercellular communication [36] , and some circulating miRs are correlated with brain miR changes after stroke [37] . Previous studies have reported that knockout of miR-126 induces cardiac dysfunction [38, 39] . MiR-126 expression level in circulation is an indicator of systemic inflammatory and angiogenic status [40, 41] . MiR-126 concentration in the circulation is significantly decreased in ischemic stroke [17] and acute myocardial infarction patients [16] . In the plasma, miR-126 expression level correlates inversely with cardiac troponin-I concentration, which is a biomarker of myocardial damage [42] . Administration of miR-126 increases EC proliferation and angiogenesis and improves cardiac neovascularization and cardiac function [15] . MiR-126 upregulation by intravenous injection of a miR-126 mimic increases vascular density in the heart and improves cardiac function in an animal model of pulmonary arterial hypertension [43] . Our data show that stroke significantly decreases circulating and heart miR-126 expression compared to non-stroke mice. Knockdown of miR-126 in miR-126 EC−/− mice subjected to stroke exhibits significantly increased cardiac dysfunction compared to miR-126 fl/fl with stroke mice. MiR-126 EC−/− stroke mice exhibit significantly increased cardiac fibrosis and hypertrophy compared to miR-126 fl/fl stroke mice. In vitro, we also found that ECs secrete miR-126. MiR-126 fl/fl -EC-Exo treatment of cardiomyocytes subjected to OGD exhibits significantly reduced hypertrophy than OGD cardiomyocytes treated with miR-126 EC−/− EC-Exo, suggesting that miR-126 ameliorates OGD-induced cardiomyocyte damage.
Many other factors may also regulate brain-heart interaction. Previous studies found that brain control of the heart is mediated through the sympathetic and parasympathetic branches of the autonomic nervous system [44] . Cardiovascular regions of the brain also regulate brain-heart interaction after stroke [45] ; for example, the right insular cortex has been implicated in cardiovascular sympathetic control [12] . In this study, to avoid the effects of direct brain lesion location of cardiac damage, we used a dMCAo model which induces ischemic lesions in the frontal and parietal cortex while the cardiovascular regions of the brain and hypothalamus are not affected [19, 20] . In addition, there was no significant difference in brain ischemic lesion volume between miR-126 fl/fl and miR-126 EC−/− stroke mice. Thus, miR-126 may facilitate brain and heart interaction, and decreasing miR-126 after stroke may contribute to induction of cardiac dysfunction. Following acute brain injury or ischemia, neuroinflammatory response that impacts recovery includes microglial activation, leukocytes infiltration into the brain, stimulation and secretion of proinflammatory factors, and lymphocytes [46, 47] . MiRs control cellular expression machinery acting through Bsingle miR/ multiple targets^or Bmultiple miRNAs/single targets^mecha-nisms. In our study, miR-126 EC−/− mice have significantly increased inflammatory factors expression in the heart tissue. MCP1, VCAM-1, and Spred-1 are targets of miR-126 [38] ; therefore, it is likely that stroke-induced decrease of miR-126 subsequently increased miR-126's target gene expression. Reduced miR-126 expression may induce vascular inflammation by increasing the levels of VCAM-1, fibrinogen, and leukocyte counts [32] . MiR-126 binds directly to the 3′-untranslated region of MCP-1 mRNA and controls MCP-1 production in a human monocyte/macrophage cell line [31] . Increased expression of MCP-1 in ischemic brain tissue after stroke worsens injury and is associated with the recruitment of inflammatory cells [48, 49] . Monocytes are a major source of pro-inflammatory cytokines following myocardial tissue injury [50] and are key inflammatory mediators of fibrosis in several pathological processes [48] . In this study, we found that stroke significantly increases MCP-1 and VCAM-1 expression as well as increases ED1 positive inflammatory cell numbers in the heart compared to non-stroke mice. Stroke in miR-126 EC−/− mice increased inflammatory factors and inflammatory cell numbers compared to stroke in miR-126 fl/fl mice. Therefore, decreasing miR-126 and consequently increasing MCP-1 and VCAM-1 expression in the heart may promote infiltration of inflammatory cells into the heart after stroke.
Inflammation and Cardiac Disease Chronic inflammation has been implicated to play a critical role in the development and progression of ischemic heart failure and drives persistent myofibroblast activity and cardiac fibrosis [51] . Monocytereleased TGF-β increases cardiac hypertrophy and fibrosis [51] . TGF-β is a potent stimulator of cardiac myofibroblast activation and contributes to extracellular matrix deposition in the infarct by upregulating collagen and fibronectin synthesis as well as by decreasing matrix degradation [52] . NOX2, a potent source of reactive oxygen species, promotes the transition of fibroblasts to myofibroblasts and mediates cardiac inflammation and fibrosis [53] . TGF-β stimulation also increases the expression level of NOX2 [53] . Thus, NOX2 oxidative stress mediates cardiac fibrosis through TGF-β-dependent manner [53] . We found that stroke increases heart TGF-β and NOX2 expression in the heart. Stroke in miR-126 EC−/− mice enhances TGF-β and NOX2 expression compared to stroke in miR-126 fl/ fl mice. Our data indicate that miR-126 regulates inflammatory effects and monocyte infiltration as well as regulates TGF-β and NOX2 expression. Therefore, miR-126/inflammation/oxidative stress may be involvedin stroke-inducedcardiac fibrosis and cardiac dysfunction.
Limitations of the Study Stroke regulates many miRs. We are not excluding the possibility that other factors may also contribute to brain-heart interaction after stroke. Our data establishes a direct mechanistic link between Bbrain and heart interaction^and suggests that the miR-126 signaling pathway may be involved in brain-heart interaction after stroke. Other factors, including other miRs and other targets of miR-126, may also impact brain-heart interaction and warrant further investigation.
Conclusions In this study, we found that the miR-126 signaling pathway may be involved in stroke-induced cardiac dysfunction. Regulation of miR-126 may be an important target for the development of novel therapeutic strategies to prevent heart dysfunction and progressive myocardial fibrosis after stroke.
